Baseline | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
---|---|---|---|---|---|---|---|
Absenteeism | |||||||
Eptinezumab 100 mg | 11.4 (19.4) | 4.7 (12.4) | 4.7 (11.2) | 5.8 (12.3) | 5.7 (13.3) | 6.4 (16.1) | 6.0 (15.5) |
Eptinezumab 300 mg | 12.0 (19.3) | 3.2 (8.2) | 6.3 (17.4) | 6.0 (16.9) | 4.4 (12.9) | 6.1 (15.0) | 5.2 (12.6) |
Placebo | 12.9 (20.1) | 9.5 (18.4) | 10.0 (20.3) | 11.3 (21.2) | 9.0 (17.2) | 12.2 (22.4) | 9.8 (18.7) |
Presenteeism | |||||||
Eptinezumab 100 mg | 50.8 (25.6) | 26.7 (26.6) | 26.5 (26.7) | 32.3 (28.1) | 30.4 (28.2) | 27.3 (26.2) | 28.2 (25.1) |
Eptinezumab 300 mg | 53.4 (24.0) | 26.3 (25.4) | 28.0 (26.4) | 26.1 (24.5) | 25.3 (25.3) | 26.7 (27.1) | 30.4 (27.1) |
Placebo | 51.7 (24.2) | 40.0 (25.6) | 41.7 (27.5) | 39.9 (26.2) | 42.8 (27.4) | 40.2 (29.3) | 41.5 (28.3) |
Work Productivity Loss | |||||||
Eptinezumab 100 mg | 53.7 (26.2) | 28.8 (28.0) | 28.8 (28.4) | 34.6 (29.6) | 32.5 (29.9) | 29.5 (27.9) | 30.5 (27.0) |
Eptinezumab 300 mg | 57.0 (24.1) | 27.7 (26.5) | 30.2 (27.9) | 28.1 (26.0) | 26.9 (26.5) | 29.1 (28.9) | 32.5 (28.6) |
Placebo | 55.6 (24.7) | 43.5 (27.0) | 44.6 (28.9) | 43.3 (27.7) | 45.9 (28.8) | 43.5 (31.0) | 45.0 (29.4) |
Activity Impairment | |||||||
Eptinezumab 100 mg | 58.5 (23.5) | 34.2 (28.4) | 32.7 (28.6) | 34.9 (27.1) | 31.4 (27.5) | 31.5 (27.2) | 31.0 (25.9) |
Eptinezumab 300 mg | 59.1 (23.4) | 32.6 (28.3) | 31.6 (28.2) | 31.9 (26.7) | 29.4 (27.0) | 30.5 (28.2) | 33.1 (27.0) |
Placebo | 58.7 (23.5) | 45.5 (25.4) | 44.6 (26.9) | 44.7 (26.9) | 45.5 (26.3) | 43.4 (29.0) | 45.2 (27.0) |